Regeneron Presents New Data at ASH from Advancing Hematology Pipeline across Multiple Blood Cancers and Disorders
Retrieved on:
Thursday, November 3, 2022
Allergy, Gene editing, Patent, U.S. Securities and Exchange Commission, Sanofi, FDA, Follicular lymphoma, COVID-19, Forest Law Enforcement and Governance Program, Alirocumab, Medicare, Immune system, Monoclonal antibody, Research, Biology, Inflammation, Government, Pain, Multiple myeloma, Social media, Maftivimab, Patient, Laboratory, Company, Degenerative disease, Biotechnology, Cancer, Casirivimab/imdevimab, Eye, B-cell lymphoma, Science, Learning, Severe acute respiratory syndrome coronavirus 2, Form 10-K, Nature, Safety, Judgement, Lymphatic system, Antibody, Medicine, Infection, Privacy, Health, Pharmacy, Drug development, RNA, Pharmaceutical industry, Vaccine, Regeneron Pharmaceuticals, Medicaid, Bayer
TARRYTOWN, N.Y., Nov. 3, 2022 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that new data across its hematology pipeline will be highlighted in 17 presentations at the 2022 American Society of Hematology (ASH) Annual Meeting from December 10-13 in New Orleans, LA.
Key Points:
- At Regeneron, we're applying more than three decades of biology expertise with our proprietaryVelociSuitetechnologies to develop medicines for patients with diverse blood cancers and rare blood disorders.
- Together, they provide us with unique combinatorial flexibility to develop customized and potentially synergistic cancer treatments.
- When Regeneron's co-Founder, President and Chief Scientific Officer George D. Yancopoulos was a graduate student with his mentor Frederick W. Alt.
- Financial and other information about Regeneron is routinely posted and is accessible on Regeneron's media and investor relations website ( http://newsroom.regeneron.com ) and its Twitter feed ( http://twitter.com/regeneron ).